Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs.
Peripheral blood lymphocyte subpopulations and specific IgG1 and IgG2 antibody levels were studied in 14 dogs naturally infected with Leishmania infantum using flow cytometry and ELISA. Six dogs (Group 1) were asymptomatic, and received no treatment. Samples from this group were collected from D0 to D180. The other eight dogs (Group 2) showed clinical symptoms, and were treated with Glucantime (from D0 to D40), with samples being collected from D0 to D90. Twenty-two healthy dogs were used as a control group (Group 3). The results demonstrated changes in the lymphocyte subsets, as well as a decrease in humoral and cellular immunity, in the infected dogs. Analysis of the B-cell populations of Groups 1 and 2 showed a striking reduction in the number of CD21+ cells. There was also a reduction in the CD5+, CD4+ and CD8+ T-cell populations. Drug therapy was found to partly restore the lost immunity, essentially the cell-mediated immunity. Both IgG1- and IgG2- specific antibodies were detected in sera from the fourteen infected dogs, but the IgG2 subclass appeared to be predominant. A significant decrease in the level of IgG2 antibodies was observed in treated and untreated dogs.
Bourdoiseau
G
G
Département de Pathologie et Clinique des Carnivores Domestiques, Ecole Nationale Vétérinaire de Lyon, France.
Bonnefont
C
C
Hoareau
E
E
Boehringer
C
C
Stolle
T
T
Chabanne
L
L
D000818:Animals; D000913:Antibodies, Protozoan / Q000032:analysis*; D000917:Antibody Formation; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D004283:Dog Diseases / Q000188:drug therapy / Q000276:immunology*; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005260:Female; D005434:Flow Cytometry / Q000662:veterinary; D007111:Immunity, Cellular; D007074:Immunoglobulin G / Q000032:analysis*; D018314:Leishmania infantum / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D016131:Lymphocyte Subsets / Q000276:immunology*; D008297:Male; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D000913:Antibodies, Protozoan; D000981:Antiprotozoal Agents; D007074:Immunoglobulin G; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate